Challenges in drug discovery and description, targeting Leishmania spp.: enzymes, structural proteins and transporters
Leishmaniasis is a complex tropical disease caused by the protozoan parasite Leishmania spp. Classical chemotherapy includes pentavalent antimonial; however, pentamidine, amphotericin B, and miltefosine have been used. Chemo-resistance remains a risk for successful treatment; thus, target identifica...
Wedi'i Gadw mewn:
| Cyhoeddwyd: |
2024
|
|---|---|
| Pynciau: | |
| Mynediad Ar-lein: | http://hdl.handle.net/10872/23281 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Eitemau Tebyg: Challenges in drug discovery and description, targeting Leishmania spp.: enzymes, structural proteins and transporters
- Leishmania spp.: proficiency of drug-resistant parasites
- Sensitivity of Leishmania spp. to glibenclamide and 4-aminopyridine: a tool for the study of drug resistance development.
- Implementación del protocolo Secure Neighbor Discovery (SEND)
- Drug resistance and treatment failure in leishmaniasis: A XXI century challenge
- Drug resistance in Leishmania parasites. Consequences, Molecular Mechanisms, and possible treatments
- Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
